Sun Pharma launches app for asthma patients

The app will help doctors track treatment progress of patients and increase compliance to medication

Sun Pharmaceutical Industries has launched an innovative mobile app to connect doctors with asthma patients. The app has been developed for enabling doctors to track treatment progress of their patients and increase compliance to medication for better management of asthma, Sun Pharma said today.

It is estimated that nearly 50 per cent to 70 per cent patients in India do not adhere to asthma treatment regimen recommended by a doctor. Sun Pharma's RespiTrack app aims to address these and other reasons leading to non-adherence thereby improving compliance to Asthma treatment through recurring medication reminders, pre-programmed alerts, over-the-air review by the doctor etc.

Read more from our special coverage on "SUN PHARMA"

• Sun Pharma says phase-3 trials in skin disorder drug show positive results
• Sun Pharma partners ICGEB to develop dengue drug
• Sun Pharma shares up 2% as it gets approval for non-steroid drug
• Sun gets US FDA nod for eye drug
• Sun Pharma buys Novartis brands for Rs 1,900 cr

"Unlike other chronic illnesses where non-adherence to treatment regimen could have significant impact on the patient's health, asthmatics tend to be low on the short-run adversity impact of non-adherence. However, in the long run, the implications of non-adherence to prescribed asthma treatment can severely impede quality of life of these patients. By leveraging our digital technology capabilities, we believe RespiTrack can address this unmet need by reducing non-adherences incidences to treatment," said Sun Pharma's India Business CEO Abhay Gandhi.